Navigation Links
Cancer Research UK Offers New Hope To Cancer Patients

In a new clinical development partnership being launched by the Cancer Research UK, and its commercial arm, Cancer Research Technology (CRT) plans to take up// drug candidates that pharmaceuticals companies have ‘deprioritised’ for not showing enough commercial promise following their preclinical studies. By this they plan to develop new treatments from anti-cancer drugs that have been shelved by pharmaceutical and biotechnology companies.

Under the scheme, companies will hand over molecules that once showed promise, but were never developed, and CRT will take on the clinical trials for those molecules. It is proposed that the Pharma and biotech firms will keep the intellectual property rights to the molecules they had shelved. After CRT has done clinical trials, the company will be given the option to take the molecule back and develop it themselves, or to leave it in the hands of the CRT scientists.

Harpal Kumar CRT chief executive hopes that the scheme that would cost up to £2 million a year, will help to identify at least five more drug molecules annually, to add to CRT’s current portfolio of around 25 licensed molecules in the clinic.Kumar sounding very optimistic said that they Hopefully would be flooded with opportunities, he told reporters. Kumar was also keen to state a point that the project was not being developed as a money-spinner for the charity, but he said that the Cancer Research UK does expects to receive a share of any financial return made by the companies.

Richard Tiner, medical director of the Association of the British Pharmaceutical Industry (ABPI) said that he personally could saw no reason for the scheme to fail, but accepted that there could be legal hurdles surrounding intellectual property rights and contracts. He explained that inevitably when discussing business or IP issues there will be differences of opinion. The CRT has approached around 20 leading pharmaceutical and biotech companies, and is c lose to deals with three. Victoria John, head of licensing for the clinical development partnerships scheme, said that those three opportunities is very good at this stage.

Kumar explained that the nature of the scheme means that many of the drug candidates might be used for rare cancers, but this will not colour the decision about which drugs to develop. He explained that just because one type of cancer is common, it doesn’t mean it would get a higher priority than a rarer cancer.

ABPI’s Tiner predicts that other medical charities will be watching the process carefully.

'"/>




Related medicine news :

1. Fibroids unlikely to Turn Cancerous
2. Virus Level could Predict Cervical Cancer Risk
3. Cancer Doctors Okays Controversial Prostate Therapy
4. Potential New Cancer Gene Identified
5. Consensus on "Combination Therapy" for Breast Cancer
6. Cancers of Colon & Rectum linked to Cigarette Smoking
7. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
8. The Cancer Rumour mill working over time
9. Cancer drugs in development nearly doubled since 1995
10. Radioactive Seeds used in Prostate Cancer treatment can migrate with the body
11. Cancer patients turning to Internet for information
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/1/2016)... ... ... 2 is a set of versatile and smooth logo reveals built exclusively for Final ... a unique logo reveal in just a matter of minutes. Custom settings give the user ... add a uniquely animated logo to any photos or videos. , ProBrand Reveal comes packaged ...
(Date:4/30/2016)... ... 30, 2016 , ... Create an abstract shape animation with ... manipulate three-dimensional shapes with ease all within Apple Motion . Users have ... texture animation, opacity texture animation, overall shape texture displacement, twist, camera controls, and ...
(Date:4/30/2016)... ... April 30, 2016 , ... Dr. Trevor Gardner, President ... today signed a multifaceted agreement which will allow for the research and development ... of Natural and Applied Sciences, Allied Health and Nursing will work together to ...
(Date:4/29/2016)... ... April 30, 2016 , ... World ... the Pick Up Springboard, an automotive invention that improves the storage features of ... worth $162 billion," says Scott Cooper, CEO and Creative Director of World Patent ...
(Date:4/29/2016)... ... April 29, 2016 , ... Memorial Healthcare System ... Medical Education (ACGME) that it has received accreditation for its residency program on ... residency programs that Memorial is currently pursuing, including Pediatrics and Internal Medicine. This ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... , April 29, 2016 ... Directeur Financier Sanofi, leader ... publie ses résultats pour le premier ... Groupe, Jérôme Contamine, commente les résultats ... les perspectives pour le reste de ...
(Date:4/28/2016)... Mich. , April 28, 2016   ... . Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s ... has signed a definitive agreement to acquire Valley ... Specialty Pharmacy ("TNH"), a leading specialty pharmacy that ... Van Nuys, California . In 2015, TNH ...
(Date:4/28/2016)... BURLINGAME, Calif. , April 28, 2016 /PRNewswire/ ... first-ever widely accessible breast and ovarian cancer risk ... cancer panel analyzing 30 genes that highly impact ... and women. Available today, the Color Test analyzes ... pancreatic, prostate, stomach, and uterine cancers. The Color ...
Breaking Medicine Technology: